Chromadex Corp (CDXC) Peer Comparison
$6.76
$-0.98
(-12.66%)
As on 17-Apr-2025 09:30EDT
Market cap
$612 Mln
Revenue (TTM)
$98 Mln
P/E Ratio
71.5
P/B Ratio
11.4
Div. Yield
0 %
Edit
| Chromadex Corp (CDXC) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
612 | 16,765 | 16,261 | 13,492 | 11,994 |
Revenue ($ Mln) |
62 | 2,782 | 1,054 | 2,436 | 670 |
Net Profit ($ Mln) |
8.55 | 491.50 | 755.85 | 860.62 | -319.95 |
Net Margin (%) |
8.72 | 17.67 | 71.69 | 35.33 | -47.79 |
RoE (%) |
22.94 | 110.09 | -- | 42.98 | -71.14 |
Price to Earnings |
71.55 | 35.25 | 19.00 | 17.40 | -- |
Price-To-Book |
11.40 | 39.29 | 9.76 | 7.42 | 26.87 |
Income Statement ($ Mln)
| Chromadex Corp (CDXC) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
61.59 | 2,109.05 | 363.64 | 2,168.70 | 3.55 |
|
Cost of Revenue
|
38.01 | 1,452.75 | 44.26 | 76.22 | 18.60 |
|
Gross Profit
|
61.59 | 656.31 | 319.38 | 2,092.49 | -15.04 |
|
Operating Expenses
|
53.86 | 209.44 | 598.15 | 1,487.87 | 586.04 |
|
Operating Profit (EBIT)
|
7.73 | 446.87 | -278.76 | 604.62 | -601.08 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
8.86 | 475.92 | -373.24 | 681.64 | -612.46 |
|
Provision for Tax
|
0.31 | 71.54 | 4.84 | 160.37 | -2.77 |
|
Profit after Tax (Net Income)
|
8.55 | 404.39 | -378.08 | 521.27 | -599.49 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Chromadex Corp (CDXC) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
46.09 | 825.55 | -105.71 | 2,244.20 | 185.44 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
4.24 | 170.77 | 377.34 | 299.72 | 845.57 |
|
Current Liabilities
|
17.95 | 1,104.55 | 907.86 | 403.77 | 103.17 |
|
Total Liabilities
|
68.28 | 2,100.87 | 1,179.50 | 2,947.69 | 1,139.80 |
Assets ($ Mln)
| Chromadex Corp (CDXC) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
4.18 | 1,071.64 | 118.63 | 1,480.11 | 444.33 |
|
Current Assets
|
64.10 | 1,029.23 | 1,060.86 | 1,467.58 | 695.47 |
|
Total Assets
|
68.28 | 2,100.87 | 1,179.50 | 2,947.69 | 1,139.80 |
|
Total Debt*
|
2.65 | 149.52 | 856.62 | 190.82 | 851.91 |
|
Net Current Assets
|
46.15 | -75.32 | 153.00 | 1,063.81 | 592.30 |
Cashflow ($ Mln)
| Chromadex Corp (CDXC) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
12.11 | 608.82 | -306.20 | 699.97 | -462.85 |
|
Cash Flow from Investing Activities
|
-- | -28.31 | 6.88 | -116.78 | -420.07 |
|
Cash from Financing Activities
|
5.37 | -154.01 | 443.93 | -628.81 | 870.52 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Chromadex Corp (CDXC) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
21.25 | 48.25 | -56.08 | 21.32 | -70.85 |
|
ROE (%)
|
22.94 | 58.42 | 300.78 | 23.13 | -262.48 |
|
ROA (%)
|
13.88 | 21.52 | -37.71 | 17.70 | -62.93 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
13.88 | 19.17 | -103.97 | 24.04 | -16,882.37 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Chromadex Corp (CDXC) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.26 | 0.12 | 0.36 | 0.18 | -0.99 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
273.15 | 42.99 | 21.47 | 150.89 | -192.04 |
|
EPS Growth (%)
|
-- | 0.42 | 0.26 | 1.79 | -1.57 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Chromadex Corp (CDXC) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | 26.30 | -21.77 | 18.00 | -3.94 |
|
Price / Book Value
|
-- | 12.88 | -77.86 | 4.18 | 12.74 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-5.44 | 20.03 | -29.40 | 11.77 | -4.51 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Chromadex Corp (CDXC) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.06 | 0.18 | -8.10 | 0.09 | 4.59 |
|
Short term debt to equity ratio
|
0.02 | 0.03 | -4.65 | 0.01 | 0.03 |
|
Current Ratio
|
3.57 | 0.93 | 1.17 | 3.63 | 6.74 |
|
Quick Ratio
|
3.06 | -- | 0.84 | 3.58 | -- |
|
Interest Coverage
|
-- | 19.04 | -4.70 | -- | -17.93 |
Operating Efficiency Ratios
| Chromadex Corp (CDXC) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
12.61 | 14.06 | 45.73 | 12.24 | 0.00 |
|
Asset Turnover
|
1.00 | 1.12 | 0.36 | 0.74 | 0.00 |
|
Receivable days
|
38.56 | 51.51 | 101.52 | 42.34 | 0.00 |
|
Inventory Days
|
113.95 | 0.00 | 2,081.92 | 95.15 | -- |
|
Payable days
|
90.12 | 8.10 | 787.97 | 172.42 | 464.09 |
|
Cash Conversion Cycle
|
62.38 | 43.41 | 1,395.47 | -34.93 | -- |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
